Literature DB >> 20231398

In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.

Carmen A Molina-Torres1, Jorge Ocampo-Candiani, Adrian Rendón, Michael J Pucci, Lucio Vera-Cabrera.   

Abstract

In this work, we describe the activity of ACH-702 against clinical isolates of Mycobacterium tuberculosis and six different nontuberculous mycobacteria. The MIC(50) and MIC(90) of both susceptible and drug-resistant M. tuberculosis strains tested were 0.0625 and 0.125 microg/ml, respectively. The MIC(50) and MIC(90) values for Mycobacterium fortuitum isolates were 0.0625 microg/ml in both cases; Mycobacterium avium complex isolates showed MIC(50) and MIC(90) values of 0.25 and 4 microg/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20231398      PMCID： PMC2863650          DOI： 10.1128/AAC.01603-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.

Authors:  J Fung-Tomc; B Minassian; B Kolek; T Washo; E Huczko; D Bonner
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

3.  In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.

Authors:  Michael J Pucci; Jijun Cheng; Steven D Podos; Christy L Thoma; Jane A Thanassi; Douglas D Buechter; Gohar Mushtaq; Gerald A Vigliotti; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

4.  Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

Authors:  Radha K Shandil; Ramesh Jayaram; Parvinder Kaur; Sheshagiri Gaonkar; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

5.  Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.

Authors:  Jason A Wiles; Yongsheng Song; Qiuping Wang; Edlaine Lucien; Akihiro Hashimoto; Jijun Cheng; Christopher W Marlor; Yangsi Ou; Steven D Podos; Jane A Thanassi; Christy L Thoma; Milind Deshpande; Michael J Pucci; Barton J Bradbury
Journal:  Bioorg Med Chem Lett       Date:  2005-12-07       Impact factor: 2.823

6.  Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.

Authors:  Jason A Wiles; Qiuping Wang; Edlaine Lucien; Akihiro Hashimoto; Yongsheng Song; Jijun Cheng; Christopher W Marlor; Yangsi Ou; Steven D Podos; Jane A Thanassi; Christy L Thoma; Milind Deshpande; Michael J Pucci; Barton J Bradbury
Journal:  Bioorg Med Chem Lett       Date:  2005-12-07       Impact factor: 2.823

7.  Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.

Authors:  Haruaki Tomioka; Chiaki Sano; Katsumasa Sato; Toshiaki Shimizu
Journal:  Int J Antimicrob Agents       Date:  2002-02       Impact factor: 5.283

8.  In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.

Authors:  Enrique J Alvirez-Freites; Janna L Carter; Michael H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

9.  Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.

Authors:  Yoshihisa Kohno; Hideaki Ohno; Yoshitsugu Miyazaki; Yasuhito Higashiyama; Katsunori Yanagihara; Yoichi Hirakata; Kiyoyasu Fukushima; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191
View more
  5 in total

1.  Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.

Authors:  Kevin R Marks; Muhammad Malik; Arkady Mustaev; Hiroshi Hiasa; Karl Drlica; Robert J Kerns
Journal:  Bioorg Med Chem Lett       Date:  2011-06-06       Impact factor: 2.823

2.  In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.

Authors:  Michael J Pucci; Steven D Podos; Jane A Thanassi; Melissa J Leggio; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

Review 3.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

4.  Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages.

Authors:  Carmen A Molina-Torres; Alejandra Barba-Marines; Orestes Valles-Guerra; Jorge Ocampo-Candiani; Norma Cavazos-Rocha; Michael J Pucci; Jorge Castro-Garza; Lucio Vera-Cabrera
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-04-04       Impact factor: 3.944

Review 5.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.